{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:36:47Z","timestamp":1780504607917,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012224","name":"Stanley Foundation","doi-asserted-by":"publisher","award":["07TGF-1112"],"award-info":[{"award-number":["07TGF-1112"]}],"id":[{"id":"10.13039\/100012224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00213-018-5079-1","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T17:27:43Z","timestamp":1541006863000},"page":"3545-3558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study"],"prefix":"10.1007","volume":"235","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4933-4162","authenticated-orcid":false,"given":"Robert C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Maayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renrong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Sershen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"5079_CR1","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3945\/ajcn.110.001586","volume":"92","author":"AH Ali","year":"2010","unstructured":"Ali AH, Yanoff LB, Stern EA, Akomeah A, Courville A, Kozlosky M, Brady SM, Calis KA, Reynolds JC, Crocker MK, Barak N, Yanovski JA (2010) Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial. Am J Clin Nutr 92:1290\u20131297","journal-title":"Am J Clin Nutr"},{"key":"5079_CR2","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/ijo.2008.135","volume":"32","author":"N Barak","year":"2008","unstructured":"Barak N, Greenway FL, Fujioka K, Aronne LJ, Kushner RF (2008) Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial. Int J Obes (2005) 32:1559\u20131565","journal-title":"Int J Obes"},{"key":"5079_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/0269881115626349","volume":"30","author":"N Barak","year":"2016","unstructured":"Barak N, Beck Y, Albeck JH (2016a) Betahistine decreases olanzapine-induced weight gain and somnolence in humans. J Psychopharmacol (Oxford, England) 30:237\u2013241","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"5079_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/JCP.0000000000000489","volume":"36","author":"N Barak","year":"2016","unstructured":"Barak N, Beck Y, Albeck JH (2016b) A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain. J Clin Psychopharmacol 36:253\u2013256","journal-title":"J Clin Psychopharmacol"},{"key":"5079_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","volume":"34","author":"C Deng","year":"2010","unstructured":"Deng C, Weston-Green K, Huang XF (2010) The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuro-Psychopharmacol Biol Psychiatry 34:1\u20134","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"5079_CR6","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1177\/0269881112449396","volume":"26","author":"C Deng","year":"2012","unstructured":"Deng C, Lian J, Pai N, Huang XF (2012) Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol (Oxford, England) 26:1271\u20131279","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"5079_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00213-011-2471-5","volume":"220","author":"M Humbert-Claude","year":"2012","unstructured":"Humbert-Claude M, Davenas E, Gbahou F, Vincent L, Arrang JM (2012) Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology 220:225\u2013241","journal-title":"Psychopharmacology"},{"key":"5079_CR8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2165\/00002018-200629110-00004","volume":"29","author":"S Jeck-Thole","year":"2006","unstructured":"Jeck-Thole S, Wagner W (2006) Betahistine: a retrospective synopsis of safety data. Drug Saf 29:1049\u20131059","journal-title":"Drug Saf"},{"key":"5079_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13690-015-0088-6","volume":"73","author":"EB Ketema","year":"2015","unstructured":"Ketema EB, Kibret KT (2015) Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Arch Public Health 73:43","journal-title":"Arch Public Health"},{"key":"5079_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519\u2013526","journal-title":"Neuropsychopharmacology"},{"key":"5079_CR11","first-page":"60733","volume":"26","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 26:60733\u201360733","journal-title":"Lancet"},{"key":"5079_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pnpbp.2014.08.006","volume":"56","author":"J Lian","year":"2015","unstructured":"Lian J, Huang XF, Pai N, Deng C (2015) Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D(2) but not 5-HT2A\/2C bindings in rat brains. Prog Neuro-Psychopharmacol Biol Psychiatry 56:75\u201380","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"5079_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.phrs.2016.02.011","volume":"106","author":"J Lian","year":"2016","unstructured":"Lian J, Huang XF, Pai N, Deng C (2016) Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications. Pharmacol Res 106:51\u201363","journal-title":"Pharmacol Res"},{"key":"5079_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2133\/dmpk.20.368","volume":"20","author":"A Matsui-Sakata","year":"2005","unstructured":"Matsui-Sakata A, Ohtani H, Sawada Y (2005) Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinetics 20:368\u2013378","journal-title":"Drug Metab Pharmacokinetics"},{"key":"5079_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/14740338.2015.974549","volume":"14","author":"R Musil","year":"2015","unstructured":"Musil R, Obermeier M, Russ P, Hamerle M (2015) Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 14:73\u201396","journal-title":"Expert Opin Drug Saf"},{"key":"5079_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00004850-200503000-00007","volume":"20","author":"M Poyurovsky","year":"2005","unstructured":"Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A (2005) The effect of betahistine, a histamine H1 receptor agonist\/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 20:101\u2013103","journal-title":"Int Clin Psychopharmacol"},{"key":"5079_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00213-012-2935-2","volume":"226","author":"M Poyurovsky","year":"2013","unstructured":"Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A (2013) Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology 226:615\u2013622","journal-title":"Psychopharmacology"},{"key":"5079_CR18","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","volume":"25","author":"JL Roerig","year":"2011","unstructured":"Roerig JL, Steffen KJ, Mitchell JE (2011) Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 25:1035\u20131059","journal-title":"CNS Drugs"},{"key":"5079_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S1461145705005110","volume":"8","author":"R Smith","year":"2005","unstructured":"Smith R, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 8:183\u2013194","journal-title":"Int J Neuropsychopharmacol"},{"key":"5079_CR20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","volume":"70","author":"R Smith","year":"2009","unstructured":"Smith R, Lindenmayer J, Davis J, Kelly E, Viviano T, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S (2009) Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. J Clin Psychiatry 70:1501\u20131513","journal-title":"J Clin Psychiatry"},{"key":"5079_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.schres.2010.04.001","volume":"120","author":"R Smith","year":"2010","unstructured":"Smith R, Lindenmayer J-P, Hu Q, Kelly E, Viviano T, Cornwell J, Vaidhyanathaswamy S, Marcovina S, Davis J (2010) Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Schizophr Res 120:204\u2013209","journal-title":"Schizophr Res"},{"key":"5079_CR22","first-page":"701","volume":"53","author":"A Szelag","year":"2001","unstructured":"Szelag A, Trocha M, Merwid-Lad A (2001) Betahistine inhibits food intake in rats. Pol J Pharmacol 53:701\u2013707","journal-title":"Pol J Pharmacol"},{"key":"5079_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/cap.2017.0147","volume":"28","author":"JH Taylor","year":"2018","unstructured":"Taylor JH, Jakubovski E, Gabriel D, Bloch MH (2018) Predictors and moderators of antipsychotic-related weight gain in the treatment of early-onset schizophrenia spectrum disorders study. J Child Adolescent Psychopharmacol 28:484. \n                    https:\/\/doi.org\/10.1089\/cap.2017.0147","journal-title":"J Child Adolescent Psychopharmacol"},{"key":"5079_CR24","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/npp.2010.101","volume":"35","author":"E Weiner","year":"2010","unstructured":"Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW (2010) Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 35:2274\u20132283","journal-title":"Neuropsychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-018-5079-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-5079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-018-5079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:07:58Z","timestamp":1572466078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-018-5079-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5079"],"URL":"https:\/\/doi.org\/10.1007\/s00213-018-5079-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]},"assertion":[{"value":"14 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Investigators report no conflicts of interest relevant to this study. After the study was completed and the original paper submitted, Dr. Smith was asked to be a consultant to Abbot Pharmaceuticals on the development of a combined drug using betahistine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}